You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
九芝堂(000989.SZ):未來將加快經典名方開發項目,持續加大來源於古代經典名方的中藥複方製劑、中藥創新藥的研發力度
格隆匯 05-23 18:42

格隆匯5月23日丨九芝堂(000989.SZ)於2023年5月23日15:00-17:00召開業績説明會,交流環節中,就“九芝堂作為中華老字號TOP10,天然在經典名方上面就具有優勢,就像六味地黃丸一樣,但是我們看不到公司在這方面作出的努力。公司未來在這方面有什麼計劃?”,公司回覆稱,公司一直積極主動開展已上市獨家和重點產品的國家藥品標準提高、有效性再評價等二次開發工作,有效提升質量控制水平,加強臨牀價值研究,為產品經營提供有力的學術支持。另外,截至2022年末,中藥創新經典名方系列完成兩個項目的調研、可研報吿編制、團隊組建等立項工作,並開展藥材本草考證、飲片炮製工藝及質量的研究相關工作。未來將根據國家政策要求加快經典名方開發項目,持續加大來源於古代經典名方的中藥複方製劑、中藥創新藥的研發力度。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account